SlideShare a Scribd company logo
1 of 1
Download to read offline
Colorado School of Public Health | 13001 E. 17th Place, B119 | Aurora, CO 80045 | 303.724.4585 | http://publichealth.ucdenver.edu
Reducing Time to Bacterial Identification in Blood Stream Infections
Veronica Ann Broslawik, MLS(ASCP)CM | MPH Candidate – Epidemiology
University of Colorado Hospital | Clinical Laboratory – Microbiology
Discussion
MALDI-TOF MS significantly improves
laboratory processes for the identification
of bacteria causing BSIs. This highly
sensitive and specific test can help
physicians make informed decisions
about antibiotic therapy. While time to
identification is important, steps must also
be taken to decrease time to antibiotic
sensitivity results. Time to appropriate
therapy is one of the most modifiable risk
factors for mortality in patients with gram-
negative bacteremia. Every hour of delay
in appropriate therapy decreases survival
rates by 7.6%.
Public Health Impact
Implementation of MALDI-TOF MS
technology significantly decreased the
time to identification of gram negative
bacteria in the blood stream. Decreased
time to identification can improve patient
outcomes and ultimately play a role in
decreasing antibiotic resistance.
Acknowledgements
•Dr. Nancy Madinger & Dr. Bruce McCollister
•Deborah Havens, MLS(ASCP)
•University of Colorado Hospital Clinical
Microbiology Laboratory Staff especially
Mehdi Bandali and Elizabeth Matthys
•CSPH Fall 2014 Capstone Colleagues
Time to Identification
n
Mean
(hours)
95% CI
(hours)
Before MALDI 153 38.04 35.56 - 40.73
After MALDI 104 26.68 24.61 - 28.76
Background
Delay in identification and treatment of
bacteria in blood stream infections (BSIs)
can negatively impact patient outcomes.
Historically, identification of bacteria in
these infections is slow (18-72 hours).
Matrix Assisted Laser Desorption
Ionization, Time of Flight Mass
Spectrometry (MALDI-TOF MS) can
decrease time to identification of bacteria
in blood stream infections.
Objective
This study examined the time to
identification of gram negative bacteria in
blood stream infections before and after
implementation of MALDI-TOF MS
technology in a clinical microbiology
laboratory.
Methods
•Retrospective, quasi-experimental
before/after study
•Inclusion Criteria:
− Positive blood cultures
− June 2013 to August 2014
− Inpatients
− Gram negative rods
o examples: E. coli or Salmonella
− 1st positive culture
− Not a mixed infection
− Antibiotic sensitivity testing
MALDI-TOF MS identification
takes 7-15 hours less time
compared to phenotypic
identification (p-value <0.001).
Results
0
24
48
72
96
120
HourstoIdentification
Identifications Before and After Implementation of MALDI-TOF MS
Before MALDI After MALDI Mean Time to Identification Before MALDI = 38.04 hours Mean Time to Identification After MALDI = 26.68 hours
BloodCulture
Drawn
BeforeMALDIAfterMALDI
0 12 24 36 48 60 72
Hours After Culture Positivity
Culture
Positive
Timeto
Bacterial
Identification
Timeto
Antibiotic
Susceptibility
Results
38.04
26.68

More Related Content

What's hot

Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020hivlifeinfo
 
Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019hivlifeinfo
 
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...hivlifeinfo
 
WHAT IS CLINICAL LABORATORY SCIENCE
WHAT IS CLINICAL LABORATORY SCIENCEWHAT IS CLINICAL LABORATORY SCIENCE
WHAT IS CLINICAL LABORATORY SCIENCEShairaTeoso
 
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...HopkinsCFAR
 
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...hivlifeinfo
 
Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...
Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...
Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...LIDC
 
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...hivlifeinfo
 
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....Leonard Davis Institute of Health Economics
 
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.CBRC
 
Biomarker Discovery For Early Clin Dev Dublin Oct 2008
Biomarker Discovery For Early Clin Dev   Dublin Oct 2008Biomarker Discovery For Early Clin Dev   Dublin Oct 2008
Biomarker Discovery For Early Clin Dev Dublin Oct 2008Mike Romanos
 
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...hivlifeinfo
 
Medical Laboratory Scientist
Medical Laboratory ScientistMedical Laboratory Scientist
Medical Laboratory ScientistSheena 17
 
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...hivlifeinfo
 
Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...
Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...
Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...Canadian Organization for Rare Disorders
 
Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...
Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...
Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...Conferenceproceedings
 
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...hivlifeinfo
 

What's hot (20)

Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
 
Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019
 
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...
 
WHAT IS CLINICAL LABORATORY SCIENCE
WHAT IS CLINICAL LABORATORY SCIENCEWHAT IS CLINICAL LABORATORY SCIENCE
WHAT IS CLINICAL LABORATORY SCIENCE
 
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
 
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
 
Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...
Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...
Launch of Policy Cures: Improving Access to Diagnostics in the Developing Wor...
 
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
 
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
 
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
 
Rapid HIV Testing: Policy & Regulatory Issues
Rapid HIV Testing: Policy & Regulatory IssuesRapid HIV Testing: Policy & Regulatory Issues
Rapid HIV Testing: Policy & Regulatory Issues
 
Biomarker Discovery For Early Clin Dev Dublin Oct 2008
Biomarker Discovery For Early Clin Dev   Dublin Oct 2008Biomarker Discovery For Early Clin Dev   Dublin Oct 2008
Biomarker Discovery For Early Clin Dev Dublin Oct 2008
 
Samuel's CV.
Samuel's CV.Samuel's CV.
Samuel's CV.
 
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...
 
Medical Laboratory Scientist
Medical Laboratory ScientistMedical Laboratory Scientist
Medical Laboratory Scientist
 
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
 
Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...
Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...
Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...
 
Dried blood spot HIV testing
Dried blood spot HIV testingDried blood spot HIV testing
Dried blood spot HIV testing
 
Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...
Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...
Prevalence of Hepatitis B Virus Infection among People Attending a Hepatitis ...
 
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
 

Similar to Final Poster

n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docx
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docxn engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docx
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docxrosemarybdodson23141
 
Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis) Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis) Abdullatif Al-Rashed
 
PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....Dr. Ajit Surya Singh
 
Use of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseasesUse of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseasesimprovemed
 
How to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesHow to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesFaculty of Medicine
 
Multiplex Detection of Antimicrobial Resistance Genes.pdf
Multiplex Detection of Antimicrobial Resistance Genes.pdfMultiplex Detection of Antimicrobial Resistance Genes.pdf
Multiplex Detection of Antimicrobial Resistance Genes.pdfMaNoLo440315
 
How to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesHow to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesSampathJayaweeraJaya
 
Automatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial ParasiteAutomatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial ParasiteCSCJournals
 
High Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEPHigh Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEPHopkinsCFAR
 
Cancer and Internist - Koronadal Internist Society.pdf
Cancer and Internist - Koronadal Internist Society.pdfCancer and Internist - Koronadal Internist Society.pdf
Cancer and Internist - Koronadal Internist Society.pdfLanceCatedral
 
Inappropriate use of laboratory resources.pptx
Inappropriate use of laboratory resources.pptxInappropriate use of laboratory resources.pptx
Inappropriate use of laboratory resources.pptxMoustafa Rezk
 
Bio marker introduction
Bio marker introductionBio marker introduction
Bio marker introductionSravan Thumati
 
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
 

Similar to Final Poster (20)

Final Presentation
Final PresentationFinal Presentation
Final Presentation
 
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docx
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docxn engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docx
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docx
 
ID diagnostics
ID diagnosticsID diagnostics
ID diagnostics
 
PARASITIC INFECTIONS ...
                                               PARASITIC INFECTIONS          ...                                               PARASITIC INFECTIONS          ...
PARASITIC INFECTIONS ...
 
Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis) Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis)
 
PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....
 
172nd publication jamdsr- 7th name
172nd publication  jamdsr- 7th name172nd publication  jamdsr- 7th name
172nd publication jamdsr- 7th name
 
journal.pone.0006828.PDF
journal.pone.0006828.PDFjournal.pone.0006828.PDF
journal.pone.0006828.PDF
 
Use of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseasesUse of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseases
 
How to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesHow to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseases
 
NDBD
NDBDNDBD
NDBD
 
Multiplex Detection of Antimicrobial Resistance Genes.pdf
Multiplex Detection of Antimicrobial Resistance Genes.pdfMultiplex Detection of Antimicrobial Resistance Genes.pdf
Multiplex Detection of Antimicrobial Resistance Genes.pdf
 
How to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesHow to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseases
 
Automatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial ParasiteAutomatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial Parasite
 
High Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEPHigh Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEP
 
Cancer and Internist - Koronadal Internist Society.pdf
Cancer and Internist - Koronadal Internist Society.pdfCancer and Internist - Koronadal Internist Society.pdf
Cancer and Internist - Koronadal Internist Society.pdf
 
Invest to End TB. Save Lives
Invest to End TB. Save LivesInvest to End TB. Save Lives
Invest to End TB. Save Lives
 
Inappropriate use of laboratory resources.pptx
Inappropriate use of laboratory resources.pptxInappropriate use of laboratory resources.pptx
Inappropriate use of laboratory resources.pptx
 
Bio marker introduction
Bio marker introductionBio marker introduction
Bio marker introduction
 
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...
 

Final Poster

  • 1. Colorado School of Public Health | 13001 E. 17th Place, B119 | Aurora, CO 80045 | 303.724.4585 | http://publichealth.ucdenver.edu Reducing Time to Bacterial Identification in Blood Stream Infections Veronica Ann Broslawik, MLS(ASCP)CM | MPH Candidate – Epidemiology University of Colorado Hospital | Clinical Laboratory – Microbiology Discussion MALDI-TOF MS significantly improves laboratory processes for the identification of bacteria causing BSIs. This highly sensitive and specific test can help physicians make informed decisions about antibiotic therapy. While time to identification is important, steps must also be taken to decrease time to antibiotic sensitivity results. Time to appropriate therapy is one of the most modifiable risk factors for mortality in patients with gram- negative bacteremia. Every hour of delay in appropriate therapy decreases survival rates by 7.6%. Public Health Impact Implementation of MALDI-TOF MS technology significantly decreased the time to identification of gram negative bacteria in the blood stream. Decreased time to identification can improve patient outcomes and ultimately play a role in decreasing antibiotic resistance. Acknowledgements •Dr. Nancy Madinger & Dr. Bruce McCollister •Deborah Havens, MLS(ASCP) •University of Colorado Hospital Clinical Microbiology Laboratory Staff especially Mehdi Bandali and Elizabeth Matthys •CSPH Fall 2014 Capstone Colleagues Time to Identification n Mean (hours) 95% CI (hours) Before MALDI 153 38.04 35.56 - 40.73 After MALDI 104 26.68 24.61 - 28.76 Background Delay in identification and treatment of bacteria in blood stream infections (BSIs) can negatively impact patient outcomes. Historically, identification of bacteria in these infections is slow (18-72 hours). Matrix Assisted Laser Desorption Ionization, Time of Flight Mass Spectrometry (MALDI-TOF MS) can decrease time to identification of bacteria in blood stream infections. Objective This study examined the time to identification of gram negative bacteria in blood stream infections before and after implementation of MALDI-TOF MS technology in a clinical microbiology laboratory. Methods •Retrospective, quasi-experimental before/after study •Inclusion Criteria: − Positive blood cultures − June 2013 to August 2014 − Inpatients − Gram negative rods o examples: E. coli or Salmonella − 1st positive culture − Not a mixed infection − Antibiotic sensitivity testing MALDI-TOF MS identification takes 7-15 hours less time compared to phenotypic identification (p-value <0.001). Results 0 24 48 72 96 120 HourstoIdentification Identifications Before and After Implementation of MALDI-TOF MS Before MALDI After MALDI Mean Time to Identification Before MALDI = 38.04 hours Mean Time to Identification After MALDI = 26.68 hours BloodCulture Drawn BeforeMALDIAfterMALDI 0 12 24 36 48 60 72 Hours After Culture Positivity Culture Positive Timeto Bacterial Identification Timeto Antibiotic Susceptibility Results 38.04 26.68